Selective reporting of antidepressant trials exaggerates drug effectiveness

User rating: 4 / 5 after 1 vote(s)

Selective publication in reporting results of antidepressant trials exaggerates the effectiveness of the drugs, according to a report in the January 17 issue of the New England Journal of Medicine. The report’s primary author is Erick Turner, M.D., assistant professor of psychiatry, physiology and phamacology at Oregon Health & Science University (OHSU) and Medical Director of the Portland Veterans Affairs Medical Center’s Mood Disorders Program.


Full story »

All News summaries from Medicine & Health news
All News summaries for January 17, 2008

5 things you didn't know about... buying medication online

32 minutes ago | User rating: not rated yet
Cynthia Reilly, director of the practice development division of the American Society of Health-Systems Pharmacists, offers advice for shopping online:

Scientists go chatting to hear kids' drug concerns

48 minutes ago | User rating: not rated yet
(AP) -- It's nothing to LOL about. Students these days often have ready access to marijuana, alcohol and tobacco but they don't feel comfortable talking about the ramifications. So, some of the nation's government ...

End-of-life discussions with physicians may have benefits for patients and caregivers

53 minutes ago | User rating: not rated yet
Terminally ill patients who had end-of-life discussions with physicians were not more likely to experience emotional distress, received less aggressive medical care in their final week of life and had a better quality of ...

Older renal cancer patients appear to benefit from sorafenib treatment

54 minutes ago | User rating: not rated yet
Older and younger patients with renal cancer derive similar benefit from sorafenib therapy and tolerate the drug equally well, according to a study published online October 7 in the Journal of the National Cancer Institute.

Use of medication for enlarged prostate not associated with increased risk of hip fracture

59 minutes ago | User rating: not rated yet
Use of a class of medications for treating an enlarged prostate, known as 5-α reductase inhibitors, are not associated with an increased hip fracture risk, according to a study in the October 8 issue of JAMA.